Actinium Pharmaceuticals, Inc. (Delaware) (ATNM): Price and Financial Metrics
ATNM Price/Volume Stats
| Current price | $6.85 | 52-week high | $9.86 |
| Prev. close | $6.67 | 52-week low | $4.00 |
| Day low | $6.60 | Volume | 347,603 |
| Day high | $7.01 | Avg. volume | 330,426 |
| 50-day MA | $7.63 | Dividend yield | N/A |
| 200-day MA | $6.24 | Market Cap | 201.36M |
ATNM Stock Price Chart Interactive Chart >
Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) Company Bio
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The companys targeted radio immunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213, and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The company was founded in 2000 and is based in New York City, New York.
Latest ATNM News From Around the Web
Below are the latest news stories about ACTINIUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ATNM as an investment opportunity.
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 MutationActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 65th Annual American Society of Hematology Meeting & Exposition (ASH). The oral presentation highlighted significantly improved survival in patients with a TP53 mutation receiving Iomab-B. |
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid LeukemiaActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today highlighted four presentations at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) detailing results from the Phase 3 SIERRA trial of Iomab-B and Phase 1 trial of Actimab-A in combination with Venetoclax in patients with relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B and Actimab-A are the only two clinical |
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & ExpositionActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) being held in San Diego on December 9-12, 2023. These include an oral presentation and two poster presentations detailing results from the completed and positive Phas |
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy CombinationsActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced data was presented at Society of Immunotherapy of Cancer (SITC) 38th Annual Meeting on Saturday, November 4, 2023, further supporting Actimab-A, the Company's clinical stage targeted radiotherapeutic comprised of the CD33 targeting antibody lintuzumab and the Actinium-225 (Ac-225) alpha-particle emitting payload. |
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe, taking place November 6 – 8, 2023 in Munich, Germany. |
ATNM Price Returns
| 1-mo | -20.35% |
| 3-mo | 36.45% |
| 6-mo | 19.96% |
| 1-year | -23.03% |
| 3-year | -4.06% |
| 5-year | -26.34% |
| YTD | 34.84% |
| 2023 | -52.30% |
| 2022 | 77.20% |
| 2021 | -22.95% |
| 2020 | 19.43% |
| 2019 | -44.18% |
Loading social stream, please wait...